David T Teachey
Overview
Explore the profile of David T Teachey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
178
Citations
11602
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang Q, Boccalatte F, Xu J, Gambi G, Nadorp B, Akter F, et al.
J Exp Med
. 2025 Feb;
222(4).
PMID: 39969525
While the mutational landscape across early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) and ETP-like leukemia is known, establishing a unified framework that activates stem cell genes characteristic of these tumors...
2.
Roeten M, Van Meerloo J, Van Dijk S, Kwidama Z, Jenkins G, Teachey D, et al.
Haematologica
. 2025 Jan;
PMID: 39882653
Not available.
3.
Hughes A, Polonen P, Teachey D
Haematologica
. 2025 Jan;
PMID: 39781622
While outcomes for pediatric acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) have improved dramatically in recent decades, relapsed and refractory disease remain a significant therapeutic challenge. This is particularly...
4.
Hoff F, Sriraja L, Qiu Y, Jenkins G, Teachey D, Wood B, et al.
Cancers (Basel)
. 2025 Jan;
16(24).
PMID: 39766140
Background: The 5-year overall survival (OS) rates of T-cell lymphocytic leukemia (T-ALL) are better for children (>90%) compared to adults (~57%). The early T-cell precursor (ETP) T-ALL subtype is prognostically...
5.
Gupta S, Rau R, Kairalla J, Rabin K, Wang C, Angiolillo A, et al.
N Engl J Med
. 2024 Dec;
392(9):875-891.
PMID: 39651791
Background: B-cell acute lymphoblastic leukemia (B-cell ALL) is the most common childhood cancer. Despite a high overall cure rate, relapsed B-cell ALL remains a leading cause of cancer-related death among...
6.
Xu J, Chen C, Sussman J, Yoshimura S, Vincent T, Polonen P, et al.
Nat Cancer
. 2024 Nov;
6(1):102-122.
PMID: 39587259
Refractoriness to initial chemotherapy and relapse after remission are the main obstacles to curing T cell acute lymphoblastic leukemia (T-ALL). While tumor heterogeneity has been implicated in treatment failure, the...
7.
Diorio C, Teachey D, Grupp S
Nat Rev Clin Oncol
. 2024 Nov;
22(1):10-27.
PMID: 39548270
Chimeric antigen receptor (CAR) T cells are revolutionizing cancer therapy, particularly for haematological malignancies, conferring durable and sometimes curative responses in patients with advanced-stage disease. The CAR T cell products...
8.
9.
Gallo P, Kim J, McNerney K, Diorio C, Foley C, Kagami L, et al.
J Allergy Clin Immunol
. 2024 Sep;
155(2):594-604.e5.
PMID: 39303891
Background: Cytokines are soluble signaling proteins that regulate inflammation and coordinate immune responses. Serum cytokine panels are increasingly used in medical practice, yet our understanding of cytokines as biomarkers for...
10.